18 and older, any sex, with Cutaneous Sutures and Scar Cosmesis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Patient Posas ScorePrimary· 3 months following procedure
Scale name: Patient Observer Scar Assessment Score. Scale measures six parameters of scars, each using a 10-point scoring system (the six categories are summed to achieve the POSAS score - totals range from 6 to 60), with 1 representing normal skin \& 10 representing the most severe scar imaginable.
Group
Value
95% CI
Fast Absorbing Gut Suture Placed 2 mm Apart
10.2
± 4.7
Fast Absorbing Gut Suture Placed 5 mm Apart
11.5
± 6.4
Width of ScarSecondary· 3 months following procedure
A secondary endpoint will include the width of the scar 1 cm from midline on each side.
This measurement will be reported in mm
Group
Value
95% CI
Fast Absorbing Gut Suture Placed 2 mm Apart
0.9
± 0.6
Fast Absorbing Gut Suture Placed 5 mm Apart
0.8
± 0.4
ErythemaSecondary· 3 months following procedure
If one half of the scar has more associated erythema, this will be noted number of people with erythema after treatment will be reported
Group
Value
95% CI
Fast Absorbing Gut Suture Placed 2 mm Apart
0
Fast Absorbing Gut Suture Placed 5 mm Apart
0
Sponsor's own description
This study aims to investigate whether the spacing of the interrupted cutaneous sutures affects surgical wound cosmesis on the face and neck. In other words, the investigators would like to determine which of the following yields a more cosmetically appealing scar: many closely approximated sutures or fewer, more widely spaced sutures. The investigators wish to compare the effects of two versus five millimeter spacing between sutures.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Davis
Last refreshed: 12 May 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03330041.